AFP
MRNA icon

Ausdal Financial Partners’s Moderna MRNA Stock Holding History

Ausdal Financial Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$450K Buy
8,849
+1,540
+21% +$71.8K 0.02% 623
2025
Q4 		$216K Buy
+7,309
New +$199K 0.01% 871
2024
Q3 		– Sell
-1,967
Closed -$234K – 538
2024
Q2 		$234K Buy
+1,967
New +$249K 0.02% 445
2023
Q3 		– Sell
-1,945
Closed -$236K – 451
2023
Q2 		$236K Sell
1,945
-330
-15% -$44K 0.03% 363
2023
Q1 		$349K Buy
2,275
+234
+11% +$38.6K 0.05% 309
2022
Q4 		$367K Buy
+2,041
New +$334K 0.05% 294
2022
Q3 		– Sell
-1,675
Closed -$239K – 466
2022
Q2 		$239K Buy
1,675
+473
+39% +$67.6K 0.04% 388
2022
Q1 		$207K Buy
1,202
+142
+13% +$23.9K 0.03% 445
2021
Q4 		$269K Buy
1,060
+309
+41% +$90.3K 0.04% 392
2021
Q3 		$289K Buy
+751
New +$277K 0.04% 367
2021
Q2 		– Sell
-1,564
Closed -$205K – 482
2021
Q1 		$205K Sell
1,564
-1,994
-56% -$289K 0.03% 413
2020
Q4 		$278K Buy
3,558
+244
+7% +$24.7K 0.05% 325
2020
Q3 		$234K Buy
+3,314
New +$231K 0.06% 303

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ausdal Financial Partners's MRNA Position: Q1 2026 in Review

Ausdal Financial Partners increased its Moderna (MRNA) stake by 21% in Q1 2026, buying an estimated $71.8K and bringing the position to 8,849 shares worth $450K. The position accounts for 0.02% of the portfolio, ranked #623.

Ausdal Financial Partners first reported a position in MRNA in Q3 2020 and has held it in 13 quarters since. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Ausdal Financial Partners held 8,849 shares of Moderna worth $450K as of Q1 2026.
  • Ausdal Financial Partners bought 1,540 Moderna shares in Q1 2026, an estimated $71.8K.
  • Moderna made up 0.02% of Ausdal Financial Partners's portfolio in Q1 2026, its #623 holding.
  • Ausdal Financial Partners first reported a position in Moderna in Q3 2020 and has held it in 13 quarters since.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Ausdal Financial Partners's 13F filing for Q1 2026, filed 12 May 2026.